Pathogenicity of IgE in autoimmunity: Successful treatment of bullous pemphigoid with omalizumab - 15/08/11
J.A.F. is supported by a Merit Review Award from the Veterans Administration and the Institute for Clinical and Translational Science at the University of Iowa (1UL1RR024979). K.A.N.M. is supported in part by the Biological Sciences Funding Program, Office of the Vice President of Research, University of Iowa. The omalizumab utilized in this study was provided by Genentech, Inc (San Francisco, Calif). |
|
Disclosure of potential conflict of interest: The authors have declared that they have no conflict of interest. |
Vol 123 - N° 3
P. 704-705 - mars 2009 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?